OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!


Research News

Hormone Therapy Safe After Nonserous Ovarian Cancer

(April 25, 2016) New findings published online this month in Obstetrics and Gynecology suggest that hormone therapy (HT) can be used safely to manage menopausal symptoms in women who have undergone treatment for nonserous epithelial ovarian cancer. The study showed no reduction in overall survival with... 

OCRFA Statement on Results of GOG 252

Many members of the ovarian cancer community have been concerned about the results of GOG 252 clinical trial, which were released last month at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer. OCRFA consulted with a team of our scientific experts, and the consensus of the group... 

Updated ICON6 Final Progression Free Survival analysis

(March 31, 2016) The Lancet has recently published an update to the progression-free survival (PFS) data of the ICON6 trial.  (The preliminary data was first presented at the European Society of Medical Oncology congress in 2013.) ICON6 is a randomized three-arm, three stage, double-blind, placebo-controlled...